Mark Searcey

Prof. Dr. Mark Searcey

School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
ZGZoë Rachael Goddard
Zoë Rachael Goddard
MMMaría J. Marín
María J. Marín
DRDavid A. Russell
David A. Russell
MSMark Searcey
Mark Searcey
Gold nanoparticles are excellent delivery systems, but how can we get them where we want them to go?

31 March 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ASAlex Shaginian
Alex Shaginian
LWLandon R. Whitby
Landon R. Whitby
SHSukwon Hong
Sukwon Hong
IHInkyu Hwang
Inkyu Hwang
BFBilal Farooqi
Bilal Farooqi
DBDale L. Boger
Dale L. Boger

14 March 2012 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
RSRichard Steel
Richard Steel
JCJonathan Cowan
Jonathan Cowan
EPEstelle Payerne
Estelle Payerne
MOMaria A. O'Connell
Maria A. O'Connell
MSMark Searcey
Mark Searcey
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is increasingly recognized as a central regulator of multiple signaling pathways in inflammation and cancer, and the ability to use chemical biological tools to investigate its biological effects is very attractive. A peptide comprising a TAT-conjugated Nrf2 sequence is shown to activate Nrf2 and its downstream target gene heme-oxygenase-1 (HO-1) in a dose-dependent manner in intact human THP-1 monocytes. Levels of Nrf2 protein peak after 3 h, whereas HO-1 mRNA and protein peak after 6 and 12 h, respectively. The peptide is also shown to inhibit the production of the pro-inflammatory cytokine TNF. The TAT-14mer constitutes a useful chemical biology tool with potential therapeutic applications.

13 November 2006 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
SDSimon Dawson
Simon Dawson
JMJohn P. Malkinson
John P. Malkinson
DPDavid Paumier
David Paumier
MSMark Searcey
Mark Searcey
Covering: up to 2005 Echinomycin is the prototypical bisintercalator, a molecule that binds to DNA by inserting two planar chromophores between the base-pairs of duplex DNA, placing its cyclic depsipeptide backbone in the minor groove. As such, it has been the focus of an extensive number of investigations into its biological activity, nucleic acid binding and, to some extent, its structure–activity relationships. However, echinomycin is also the parent member of an extended family of natural products that interact with DNA by a similar mechanism of bisintercalation. The structural variety in these compounds leads to changes in sequence selectivity and biological activity, particularly as anti-tumour and anti-viral agents. One of the more recently identified marine natural products that is moving close to clinical development is thiocoraline, and it therefore seems timely to review the various bisintercalator natural products.

25 April 2017 in Inorganic Chemistry
Verified
Journal Article
Open access
BBBenoît Bertrand
Benoît Bertrand
JFJulio Fernandez-Cestau
Julio Fernandez-Cestau
JAJesus Angulo
Jesus Angulo
MCMarco M. D. Cominetti
Marco M. D. Cominetti
ZWZoё Waller
Zoё Waller
MBManfred Bochmann
Manfred Bochmann
The synthesis of a series of cyclometalated gold(III) complexes supported by pyrazine-based (C^N^C)-type pincer ligands is reported, including the crystal structure of a cationic example. The compounds provide a new platform for the study of antiproliferative properties of gold(III) complexes. Seven complexes were tested: the neutral series (C^Npz^C)AuX [X = Cl (1), 6-thioguanine (4), C≡CPh (5), SPh (6)] and an ionic series that included the N-methyl complex [(C^NpzMe^C)AuCl]BF4 (7) and the N-heterocyclic carbene complexes [(C^Npz^C)AuL]+ with L = 1,3-dimethylbenzimidazol-2-ylidene (2) or 1,3,7,9-tetramethylxanthin-8-ylidene (3). Tests against human leukemia cells identified 1, 2, 3, and 4 as particularly promising, whereas protecting the noncoordinated N atom on the pyrazine ring by methylation (as in 7) reduced the cytotoxicity. Complex 2 proved to be the most effective of the entire series against the HL60 leukemia, MCF-7 breast cancer, and A549 lung cancer cell lines, with IC50 values down to submicromolar levels, associated with a lower toxicity toward healthy human lung fibroblast cells. The benzimidazolylidene complex 2 accumulated more effectively in human lung cancer cells than its caffeine-based analogue 3 and the gold(III) chloride 1. Compound 2 proved to be unaffected by glutathione under physiological conditions for periods of up to 6 days and stabilizes the DNA G-quadruplex and i-motif structures; the latter is the first such report for gold compounds. We also show the first evidence of inhibition of MDM2–p53 protein–protein interactions by a gold-based compound and identified the binding mode of the compound with MDM2 using saturation transfer difference NMR spectroscopy combined with docking calculations.

15 May 2007 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
ABAnna L. Brogden
Anna L. Brogden
NHNicholas H. Hopcroft
Nicholas H. Hopcroft
MSMark Searcey
Mark Searcey
CCChristine Cardin
Christine Cardin